Advertisement

Structural and inhibition analysis of novel sulfur-rich 2-mercaptobenzothiazole and 1,2,3-triazole ligands against Mycobacterium tuberculosis DprE1 enzyme

  • Sumita Karan
  • Vipin K. Kashyap
  • Syed Shafi
  • Ajay K. SaxenaEmail author
Original Paper

Abstract

Mycobacterium tuberculosis decaprenylphosphoryl-β-d-ribose oxidase (MtbDprE1) acts in concert with decaprenylphosphoryl-β-d-ribose 2-epimerase (MtbDprE2) and catalyzes the epimerization of DPR into DPA. DPA is the sole precursor for synthesis of arabinogalactan and lipoarabinomannan in the mycobacterial cell wall. MtbDprE1 is a unique antimalarial drug target and many covalent and non-covalent inhibitors against MtbDprE1 have been studied for their antituberculosis activities. In the current study, we have purified MtbDprE1 enzyme and synthesized six sulfur-rich 2-mercaptobenzothiazole and 1, 2, 3-triazole conjugated ligands and performed binding analysis with MtbDprE1. All ligands have shown competitive binding, as observed for other covalently and noncovalently bound MtbDprE1 inhibitors. Molecular docking analysis of six ligands with MtbDprE1 shows that they occupy the substrate binding pocket of MtbDprE1 and are stabilized by hydrogen bonds and van der Waals interactions. Our study shows that sulfur-rich 2-mercaptobenzothiazole ligands act as specific inhibitors against MtbDprE1 and could be used as antituberculosis agents.

Keywords

Mycobacterial cell wall synthesis enzyme In vitro MtbDprE1-FAD ~ ligand binding In silico MtbDprE1-FAD-ligand structure 

Notes

Acknowledgements

Funding for the current work was supported by a grant from the Department of Biotechnology (No. PAC-SLS-AKS-DBT-01131216-737) to Ajay K Saxena. Partial funding from UGC resource networking, DST–PURSE, and UPE-II grants from Jawaharlal Nehru University are gratefully acknowledged. Sumita Karan and Vipin K. Kashyap were supported by UGC-NET research fellowship. The authors thank Amarjeet Kumar, Prof. N. SubbaRao’s student, who helped tremendously in docking analysis of these compounds. The authors thank AIRF facility of JNU for conducting the surface plasmon resonance experiment.

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest.

Supplementary material

894_2017_3403_MOESM1_ESM.pdf (42 kb)
Supplementary Fig. 1 Secondary structure assignment and sequence alignment of MtbDprE1 from related mycobacterial species. All DprE1 sequences are aligned using MultiAln program (Multiple sequence alignment with hierarchical clustering “F. CORPET,1988, Nucl. Acids Res., 16 (22), 10,881–10,890) and formatted using Espript3 program (Robert, X. and Gouet, P. (2014) “Deciphering the key features in protein structures with new ENDscript server” Nucl. Acids Res. 42(W1),W320-W324. (PDF 41 kb).

References

  1. 1.
    World Health Organization (2015) Global Tuberculosis ReportGoogle Scholar
  2. 2.
    Kieser K, Rubin JE (2014) How sisters grow apart: mycobacterial growth and division. Nat Rev Microbiol 12:550–562CrossRefGoogle Scholar
  3. 3.
    Bhutani I, Loharch S, Gupta P, Madathil R, Parkesh R (2015) Structure, dynamics, and interaction of Mycobacterium tuberculosis (Mtb) DprE1 and DprE2 examined by molecular modeling, simulation, and electrostatic studies. PLoS One 10(3):e0119771CrossRefGoogle Scholar
  4. 4.
    Mikusova K, Huang HR, Yagi T, Holsters M, Vereecke D, D’Haeze W, Scherman MS, Brennan PJ, McNeil MR, Crick DC (2005) Decaprenylphosphoryl arabinofuranose, the donor of the d-arabinofuranosyl residues of mycobacterial arabinan, is formed via a two-step epimerization of decaprenylphosphoryl ribose. J. Bacteriol. 187(23):8020–8025CrossRefGoogle Scholar
  5. 5.
    Wolucka BA (2008) Biosynthesis of d-arabinose in mycobacteria—a novel bacterial pathway with implications for antimycobacterial therapy. FEBS J. 275(11):2691–2711CrossRefGoogle Scholar
  6. 6.
    Christophe TJ, MJeon HK, Fenistein D, Contreras-Dominguez M, Kim JG, et al. (2009) High content screening identifies decaprenyl-phosphoribose 2′ epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog. 5(10):e1000645CrossRefGoogle Scholar
  7. 7.
    Manina G, Pasca MR, Buroni S, De Rossi ERG (2010) Decaprenylphosphoryl-beta-d-ribose 2′-epimerase from Mycobacterium tuberculosis is a magic drug target. Curr. Med. Chem. 17(27):3099–3108CrossRefGoogle Scholar
  8. 8.
    Piton J, Foo CSY, Cole ST (2017) Structural studies of Mycobacterium tuberculosis DprE1 interacting with its inhibitors. Drug Discov. Today 22(3):526–533CrossRefGoogle Scholar
  9. 9.
    Magnet S, Hartkoorn CR, Szekely R, Pato J, Triccas AJ, Cole ST (2010) Leads for antitubercular compounds from kinase inhibitor library screens. Tuberculosis 90(6):354–360CrossRefGoogle Scholar
  10. 10.
    Stanley SA, Grant SS, Kawate T, Iwase N, Shimizu M (2012) Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. ACS Chem Biol 7(8):1377–1384CrossRefGoogle Scholar
  11. 11.
    Makarov V, Manina G, Mikusova K, Möllmann U, Ryabova O, Cole ST (2009) Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324(5928):801–804CrossRefGoogle Scholar
  12. 12.
    Batt SM, Jabeen T, Bhowruth V, Quill L, Lund PA, Eggeling L, Alderwick LJ, Fütterer K, Besra GS (2012) Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors. Proc. Natl. Acad. Sci. 109(28):11354–11359CrossRefGoogle Scholar
  13. 13.
    Neres J, Pojer F, Molteni E, Chiarelli LR, Dhar N, Boy-Röttger S, Buroni S, et al. (2012) Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis. Sci. Transl. Med. 4(150):150ra121CrossRefGoogle Scholar
  14. 14.
    Makarov V, Neres J, Hartkoorn RC, Cole ST (2015) The 8-pyrrole-Benzothiazinones are noncovalent inhibitors of DprE1 from Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 59(8):4446–4452CrossRefGoogle Scholar
  15. 15.
    Tiwari R, Miller PA, Chiarelli LR, Mori G, Šarkan M, Centárová I, Cho S, Mikušová K, Franzblau SG, Oliver AG, Miller MJ (2016) Design, syntheses, and anti-TB activity of 1,3-benzothiazinone azide and click chemistry products inspired by BTZ043. ACS Med. Chem. Lett. 7(3):266–270CrossRefGoogle Scholar
  16. 16.
    Mir FS, Zaman S, Kalia MS, Rajput NP, Mulakayala VS, Mulakayala C, Khan N, Alam IA, Alam MS (2014) Sulfur-rich 2-mercaptobenzothiazole and 1,2,3-triazole conjugates as novel antitubercular agents. Eur. J. Med. Chem. 76:274–283CrossRefGoogle Scholar
  17. 17.
    Rashmi M, Swati D (2015) In silico drug re-purposing against African sleeping sickness using GlcNAc-PI de-N-acetylase as an experimental target Comput. Biol. Chem. 59:87–94CrossRefGoogle Scholar
  18. 18.
    Pulaganti M, Banaganapalli B, Mulakayala C, Chitta SK, Anuradha CM (2014) Molecular modeling and docking studies of O-succinylbenzoate synthase of M. tuberculosis--a potential target for antituberculosis drug design Appl. Biochem. Biotechnol. 172(3):1407–1432CrossRefGoogle Scholar
  19. 19.
    Bessonov K, Vassall KA, Harauz G (2017) Docking and molecular dynamics simulations of the Fyn-SH3 domain with free and phospholipid bilayer-associated 18.5-kDa myelin basic protein (MBP) - Insights into a non-canonical and fuzzy interaction. Proteins prot.25295Google Scholar
  20. 20.
    Ali R, Kumar S, Afzal O, Bawa S (2015) In vitro antimicrobial screening and molecular docking studies of synthesized 2-chloro-N-(4-phenylthiazol-2-yl) acetamide derivatives. Drug Development and Therapeutics 6(2):79–87CrossRefGoogle Scholar
  21. 21.
    Panda SK, Mahapatra RK (2017) In-silico screening, identification and validation of a novel vaccine candidate in the fight against Plasmodium falciparum. Parasitol. Res. 116(4):1293–1305CrossRefGoogle Scholar
  22. 22.
    Adhikari UK, Rahman MM (2017) Comparative analysis of amino acid composition in the active site of nirk gene encoding copper-containing nitrite reductase (CuNiR) in bacterial spp. Comput. Biol. Chem. 67:102–113CrossRefGoogle Scholar
  23. 23.
    Al-Khayyat MZ, Al-Dabbagh AG (2016) In silico prediction and docking of tertiary structure of LuxI, an inducer synthase of Vibrio fischeri. Rep Biochem Mol Biol 4(2):66–75Google Scholar
  24. 24.
    Satar R, Ismail SA, Rehan M, Ansari SA (2016) Elucidating the binding efficacy of β-galactosidase on graphene by docking approach and its potential application in galacto-oligosaccharide production. Bioprocess Biosyst. Eng. 39(5):807–814CrossRefGoogle Scholar
  25. 25.
    Matossian M, Vangelderen C, Papagerakis P, Zheng L, Wolf GT, Papagerakis S (2014) In silico modeling of the molecular interactions of antacid medication with the endothelium: novel therapeutic implications in head and neck carcinomas. Int. J. Immunopathol. Pharmacol. 27(4):573–583CrossRefGoogle Scholar
  26. 26.
    Poorebrahim M, Sadeghi S, Ghorbani R, Asghari M, Abazari MF, Kalhor H, Rahimi H (2017) In silico enhancement of the stability and activity of keratinocyte growth factor. J. Theor. Biol. 418:111–121CrossRefGoogle Scholar
  27. 27.
    Li H, Jogl G (2013) Crystal structure of decaprenylphosphoryl-beta- d-ribose 2′-epimerase from Mycobacterium smegmatis Proteins 81(3):538–543CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Sumita Karan
    • 1
  • Vipin K. Kashyap
    • 1
  • Syed Shafi
    • 2
  • Ajay K. Saxena
    • 1
    Email author
  1. 1.Structural Biology Lab, School of Life SciencesJawaharlal Nehru UniversityNew DelhiIndia
  2. 2.Department of Chemistry, Faculty of ScienceJamia HamdardNew DelhiIndia

Personalised recommendations